Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...
Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...
With speculation online about OpenAI having reached the AGI stage of ChatGPT development, Sam Altman says that's not what's ...
OpenAI CEO Sam Altman is under fire for suggesting that artificial intelligence will upend societal norms after President ...
OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI ...
OpenAI has recently released its first AI agent, Operator. But how is it different from the ChatGPT platform? Let's find out.
Sam Altman's comments came amid a flurry of online exchanges between himself, Musk, and Microsoft over the $500 billion ...